Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xitabin
- Development stage
- Unknown
- Lead developer
- Beacon Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Xitabin is an oral chemotherapy medication containing capecitabine, developed and manufactured by Beacon Pharmaceuticals. It serves as a prodrug that undergoes a three-step enzymatic conversion to 5-fluorouracil (5-FU), with the final conversion often occurring within tumor tissues via the enzyme thymidine phosphorylase. The active metabolite, 5-FU, inhibits thymidylate synthase, an enzyme essential for the synthesis of thymidine monophosphate, thereby disrupting DNA synthesis and slowing the growth of cancer cells. Xitabin is indicated for the treatment of various solid tumors, including metastatic colorectal cancer, adjuvant colon cancer (Dukes' C), metastatic breast cancer (as monotherapy or in combination with docetaxel), and cancers of the gastric, esophageal, and pancreatic systems.
- Brand names
- Xitabin
- Other names
- capecitabine
02
Targets
TS (Thymidylate synthase)
Beyond the preview
Go deeper on Xitabin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xitabin.